Compare CAQ & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAQ | VRXA |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.9M | 263.0M |
| IPO Year | 2025 | 2025 |
| Metric | CAQ | VRXA |
|---|---|---|
| Price | $10.03 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 104.1K | ★ 376.0K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $1.27 |
| 52 Week High | $10.05 | $4.50 |
| Indicator | CAQ | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 36.91 |
| Support Level | $9.97 | $1.27 |
| Resistance Level | $10.05 | $1.99 |
| Average True Range (ATR) | 0.01 | 0.17 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 73.75 | 25.71 |
Cambridge Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.